All In Biotech

Drug Trial Radar · NCT06685835

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - The CEDAR Study

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 214 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

214

Actual

Start

Dec 16, 2024

Primary completion

Feb 12, 2026

Study completion Jun 8, 2026

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Nov 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • BrensocatibDrug

    Film-coated Oral tablet

  • PlaceboDrug

    Film-coated Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Week 16Time frame: Baseline and Week 16

Locations

72 sites in 10 countries. Site status is shown where the registry gives one.

  • USA001

    Phoenix, Arizona

  • USA007

    Sacramento, California

  • USA026

    Coral Gables, Florida

  • USA027

    Hollywood, Florida

  • USA021

    Margate, Florida

  • USA018

    Miami, Florida

  • USA025

    Ocala, Florida

  • USA004

    Tampa, Florida

  • USA010

    Weston, Florida

  • USA028

    Atlanta, Georgia

  • USA011

    Sandy Springs, Georgia

  • USA003

    Plainfield, Indiana

  • USA002

    Baton Rouge, Louisiana

  • USA017

    Boston, Massachusetts

  • USA012

    Detroit, Michigan

  • USA024

    Fort Gratiot, Michigan

  • USA020

    Minneapolis, Minnesota

  • USA015

    St Louis, Missouri

  • USA013

    Lebanon, New Hampshire

  • USA009

    Cleveland, Ohio

  • USA016

    Springfield, Ohio

  • USA019

    Hershey, Pennsylvania

  • USA022

    Philadelphia, Pennsylvania

  • USA005

    Dallas, Texas

  • USA023

    Dallas, Texas

  • USA008

    Spokane, Washington

  • AUS003

    Darlinghurst, New South Wales, Australia

  • AUS004

    Kogarah, New South Wales, Australia

  • AUS001

    Brisbane, Queensland, Australia

  • AUS006

    Woolloongabba, Queensland, Australia

  • AUS002

    Fremantle, Western Australia, Australia

  • BGR001

    Lovech, Bulgaria

  • BGR003

    Pleven, Bulgaria

  • BGR004

    Sofia, Bulgaria

  • BGR002

    Stara Zagora, Bulgaria

  • CAN004

    Québec, Canada

  • CAN003

    Barrie, Ontario, Canada

  • CAN006

    Guelph, Ontario, Canada

  • CAN007

    Peterborough, Ontario, Canada

  • CAN011

    Richmond Hill, Ontario, Canada

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.